Preparation method and application of a nitroreductase-activated multifunctional molecular prodrug for overcoming tumor oxygen heterogeneity distribution

By designing the fluoroboron dipyrrole-nitrobenzene-camptothecin conjugate, the synergistic effect of photodynamic therapy and chemotherapy was used to solve the treatment difficulties caused by tumor oxygen heterogeneity, and effective treatment for the whole tumor was achieved and improved The treatment efficiency is reduced and the toxicity and resistance of the drug are reduced.

CN115806566BActive Publication Date: 2024-11-01FUZHOU UNIV
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202211569037.7
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Filing Date
2022-12-08
Publication Date
2024-11-01
Estimated Expiration
2042-12-08

AI Technical Summary

Technical Problem

Tumor oxygen heterogeneity causes existing hypoxia response prodrugs to treat tumor hypoxia only and cannot effectively target the entire tumor, resulting in difficulty in recurring cancer.

Method used

Design a multifunctional molecular prodrug that uses photodynamic therapy to form a fluoroboron dipyrrole-nitrobenzene-camptothecin conjugate by connecting the fluoroboron dipyrrole photosensitizer to the camptothecin to form a fluoroboron dipyrrole-nitrobenzene-camptothecin conjugate and using photodynamic therapy and The synergistic effect of chemotherapy activates nitrophenyl groups to release chemotherapy drugs in both the normal and hypoxic areas, making up for the shortcomings of photodynamic therapy.

Benefits of technology

The coordinated treatment of whole tumors was achieved, the treatment difficulties of oxygen distribution heterogeneity were overcome, the treatment efficiency was significantly improved, and the systemic toxicity of the drug and the resistance of the tumor were reduced.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN115806566B_ABST
    Figure CN115806566B_ABST
Patent Text Reader

Abstract

The present invention discloses a method for preparing a multifunctional molecular prodrug activated by nitroreductase for overcoming the heterogeneity of tumor oxygen distribution and its application, which utilizes cytotoxic quinoline alkaloid chemotherapy drug camptothecin, and introduces a nitrobenzene-modified fluoroboron dipyrrole photosensitizer of tumor hypoxia response at its active site to obtain a fluoroboron dipyrrole-nitrobenzene-camptothecin conjugate, which combines the chemotherapy effects of photodynamic and hypoxia activation, can overcome the problem of tumor oxygen distribution heterogeneity and achieve full tumor treatment. The present invention prepares a fluoroboron dipyrrole-nitrobenzene-camptothecin conjugate, which is used to overcome the problem of tumor oxygen distribution heterogeneity and achieve the goal of full tumor treatment. The synthesis method of the present invention is simple, the raw materials are easily available, the cost is low, the side reactions are few, the yield is high, it is easy to purify, and it is conducive to industrial production.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention belongs to the field of anticancer drug design and synthesis, and specifically relates to a preparation method and application of a multifunctional molecular prodrug activated by nitroreductase for overcoming the heterogeneous distribution of tumor oxygen. Background Art

[0002] Tumor hypoxia is caused by the uncontrollable proliferation of tumor cells and is one of the important characteristics of the tumor microenvironment. It manifests itself in the fact that the oxygen content level in the tumor tissue cells is significantly lower than that in the normal tissue cells. In response to this phenomenon, scientists have used hypoxia-responsive functional groups (such as nitroaromatic derivatives, azobenzene, and quinone derivatives) to chemically modify active drugs (such as paclitaxel, camptothecin, and doxorubicin) to develop hypoxia-responsive prodrugs. This prodrug protects and functionalizes the active sites of the active drug, thereby improving the specificity of the drug for tumor tissue treatment and reducing the systemic toxicity of the drug. However, in solid tumors, oxygen distribution is heterogeneous. Tissue cells close to blood vessels are still in a normal oxygen state, and tumor areas far from blood vessels are in a hypoxic state, resulting in significant differences in the oxygen content of the entire tumor tissue. Therefore, hypoxia-responsive prodrugs have great application limitations. They can only treat hypoxic areas of tumors, but residual tumor tissue cells will still lead to cancer recurrence.

[0003] Recently, the combined treatment model of photodynamic therapy and chemotherapy has been widely studied. This combined treatment method can significantly improve the efficiency of cancer treatment, reduce the dosage of drugs, and reduce the drug resistance of lesion tissues. Photodynamic therapy (PDT) is an early-developed minimally invasive light therapy, and in recent years it has been gradually applied to the diagnosis and treatment of clinical cancer. Compared with traditional treatments such as surgery, radiotherapy, and chemotherapy, PDT has the advantages of minimal invasiveness, high selectivity, low side effects, no drug resistance, and a wide spectrum of tumor treatment. During the PDT process, light of a specific wavelength locally irradiates the tumor site to excite the photosensitizer enriched in the tumor tissue. The excited photosensitizer transfers energy with molecular oxygen in the tumor tissue to produce singlet oxygen (Singlet oxygen, 1 O2). 1 O2 has strong oxidative properties and can induce cell apoptosis or necrosis. In addition, PDT is a precise light-controlled treatment method. 1 O2, it can quickly consume oxygen in tumor tissue and cause severe hypoxia. Therefore, the integration of photosensitizers and hypoxia-responsive prodrugs can maximize the effects of photodynamic therapy and hypoxia-responsive chemotherapy, achieve synergistic treatment, and overcome the treatment difficulties caused by the heterogeneity of oxygen distribution in tumor tissues, thus achieving full tumor treatment. Summary of the invention

[0004] The purpose of the present invention is to provide a method for preparing a multifunctional molecular prodrug activated by nitroreductase for overcoming the heterogeneous distribution of oxygen in tumors and its application. The present invention utilizes a hypoxia-responsive nitrobenzene linker to covalently link the chemotherapy drug camptothecin (CPT) and a fluoroboron dipyrrole photosensitizer to obtain a single-molecule prodrug that integrates photodynamic therapy and chemotherapy. Since the hydroxyl active site of CPT is modified, the cytotoxicity of CPT is inhibited, so the entire molecular prodrug has extremely low dark toxicity. The prodrug synthesized by the present invention has a simple synthesis method, is easy to purify and separate, has few side reactions, has a high yield, is easy to obtain raw materials, has a low cost, and is conducive to industrial production. The prodrug is enriched in the tumor site by tail vein injection. When local light is irradiated on tumor tissue, the drug can effectively perform photodynamic therapy in the normal oxygen area of ​​the tumor, while consuming oxygen to accelerate tumor hypoxia, promote the overexpression of nitrobenzene reductase in tumor cells, reduce the nitrophenyl group in the prodrug to aniline, and further undergo intramolecular conversion reaction to release the chemotherapy drug CPT; while the drug enriched in the hypoxic area of ​​the tumor can be reduced by the overexpressed nitroreductase and release the chemotherapy drug CPT, making up for the shortcomings of photodynamic therapy in the hypoxic area of ​​the tumor. Therefore, the prodrug is expected to overcome the treatment difficulties caused by the heterogeneity of tumor oxygen distribution and achieve the goal of achieving full tumor treatment.

[0005] To achieve the above object, the present invention adopts the following technical solution:

[0006] A multifunctional molecular prodrug activated by nitroreductase for overcoming the heterogeneity of tumor oxygen distribution, which is a fluoroboron dipyrrole-nitrobenzene-camptothecin conjugate with the chemical formula:

[0007]

[0008] The preparation method of the above compound comprises the following steps: As the starting material, the fluoroborane-dipyrrole-nitrobenzene-camptothecin conjugate was synthesized (BDP-Nitro-CPT).

[0009] Specifically: the compound Dissolve in dichloromethane at a molar ratio of 1:2.2, then add 2-3 equivalents of 4-dimethylaminopyridine (DMAP), 3 drops of N,N-diisopropylethylamine (DIPEA) and triphosgene, and vigorously stir the reaction solution for 18-36 hours at room temperature; after the reaction, extract with dichloromethane and water, dry the organic phase over anhydrous Na2SO4, and remove the solvent under reduced pressure; finally, use dichloromethane-methanol (volume ratio of 50:1) as the eluent, and separate by silica gel column chromatography to obtain a fluoroboron dipyrrole-nitrobenzene-camptothecin conjugate. (BDP-Nitro-CPT);

[0010] The 2-3 equivalents of DMAP, The molar amount of .

[0011] The preparation method of the compound 2a comprises the following steps:

[0012] (1) Phosphorus tribromide is used as the starting material to synthesize

[0013] (2) The compound synthesized in step (1) As starting materials, the compounds were synthesized

[0014] Specifically:

[0015] (1) Phosphorus tribromide was mixed in a molar ratio of 2:1 and dissolved in acetonitrile, and then reacted for 2 hours under ice bath conditions; after the reaction, the solvent was removed and separated by silica gel column chromatography using dichloromethane as the eluent to obtain a yellow solid

[0016] (2) The product was dissolved in acetone in a molar ratio of 1:2, and then 10 equivalents of potassium carbonate were added. The reaction was refluxed in an oil bath at 60°C for 1 hour. After the reaction was completed, the potassium carbonate was filtered and the solvent was removed. The product was then extracted with dichloromethane and water. The organic phase was dried over anhydrous Na2SO4 and the solvent was removed under reduced pressure. The product was then separated by silica gel column chromatography using dichloromethane-methanol (volume ratio of 50:1) as the eluent to obtain a green solid.

[0017]

[0018] The 10 equivalents of potassium carbonate are Application: The use of the multifunctional molecular prodrug activated by nitroreductase for overcoming the heterogeneity of tumor oxygen distribution in the preparation of anticancer drugs.

[0019] The fluoroboron dipyrrole-nitrobenzene-camptothecin (BDP-Nitro-CPT) prodrug is used for synergistic therapy to overcome the heterogeneity of tumor oxygen distribution.

[0020] Alkaloids are low molecular weight biological molecules with a nitrogen content of 20%. Some alkaloids have strong biological activity and are often used to treat diseases. Currently, the alkaloid anticancer drugs used in clinical practice include camptothecin, which is a type I DNA topoisomerase (Top I) inhibitor and has certain therapeutic effects on esophageal cancer, colon cancer, liver cancer and lung cancer. However, camptothecin also has some disadvantages: such as poor water solubility, unstable structure, and large systemic toxic side effects. Photosensitizers are the core elements of photodynamic therapy. Fluoroboron dipyrrole derivatives are one of the most widely studied fluorescent dyes. They meet a series of advantages of ideal photosensitizers: such as clear chemical structure, strong light absorption, high photostability, low dark toxicity, and high singlet oxygen quantum yield after heavy atom modification.

[0021] Based on this, the present invention first connects the hypoxia-responsive nitrophenyl group to the fluoroboron dipyrrole photosensitizer, and then covalently connects it to the chemotherapy drug camptothecin to form a multifunctional molecular prodrug BDP-Nitro-CPT. When the tumor site is irradiated with red light, the drug enriched in the normal oxygen area of ​​the tumor is stimulated by light to produce photodynamic activity, which then causes hypoxia in the tumor site, inducing activation of the chemotherapy drug camptothecin, and plays a role in photodynamic-chemotherapy synergistic treatment. The molecular prodrug in the hypoxic area of ​​the tumor can directly activate the chemotherapy drug camptothecin, making up for the shortcomings of photodynamic therapy in the hypoxic area of ​​the tumor. Therefore, the BDP-Nitro-CPT prodrug is expected to overcome the treatment difficulties caused by the heterogeneity of tumor oxygen distribution and achieve the purpose of whole tumor treatment.

[0022] The significant advantages of the present invention are:

[0023] (1) Camptothecin is an alkaloid that can directly destroy DNA structure. When covalently linked to the fluoroboron dipyrrole photosensitizer by a nitrobenzene linker, the stability of camptothecin in the blood circulation process can be improved and the systemic toxicity of the drug can be effectively reduced;

[0024] (2) Under hypoxic conditions or during photodynamic therapy, the nitrophenyl group of the BDP-Nitro-CPT prodrug can be directly or indirectly reduced to aniline and further undergo intramolecular conversion to release the chemotherapeutic drug camptothecin, thus playing a synergistic role in photodynamic therapy and chemotherapy.

[0025] (3) The absorption and emission spectra of the prodrug are both in the red light region. Red light has strong tissue penetration ability, is not easy to cause skin phototoxicity during photodynamic therapy, and has low dark toxicity. It is an ideal prodrug;

[0026] (4) The target prodrug has a single structure, is simple to synthesize, and the product is easy to purify;

[0027] (5) From the cytotoxicity experiments of cancer cells 4T1 (mouse breast cancer cells), HepG2 (human liver cancer cells), and HeLa (human cervical cancer cells), it can be seen that hypoxic cancer cells can induce the reduction of the nitrophenyl group in BDP-Nitro-CPT, followed by the release of the chemotherapeutic drug camptothecin. Under light conditions, the photodynamic effect of BDP-Nitro-CPT can induce cancer cells to become hypoxic and release camptothecin. BRIEF DESCRIPTION OF THE DRAWINGS

[0028] Figure 1 Light (660nm, 20mW / cm 2 , 5min) and without illumination, the cytotoxicity of BDP-Nitro-CPT and 2a to 4T1, HepG2 and HeLa cells cultured under different oxygen concentrations;

[0029] Figure 2 Study on the antitumor activity of different compounds under conditions of light exposure and without light exposure; (a) Changes in tumor volume of mice in different groups during treatment; (b) Tumor mass and (c) morphology of mice after 15 days; (d) Changes in body weight of mice within 15 days; (e) Morphological analysis of tumor tissues of mice in different groups after 15 days of treatment after H&E staining;

[0030] Figure 3 Morphological diagram of tissue sections of various organs of mice in different groups after H&E staining;

[0031] Figure 4 The mechanism of action of the prodrug of fluoroboron dipyrrole-nitrophenylcamptothecin (BDP-Nitro-CPT);

[0032] Figure 5 Compound 1a in CDCl3 1 H NMR spectrum;

[0033] Figure 6 Compound 1a in CDCl3 13 C NMR spectrum;

[0034] Figure 7 is the high resolution mass spectrum (HRMS) of compound 1a;

[0035] Figure 8 Compound 2a in CDCl3 1 H NMR spectrum;

[0036] Fig. 9 Compound 2a in CDCl3 13 C NMR spectrum;

[0037] Fig.10 is the HRMS spectrum of compound 2a;

[0038] Fig.11 For the compound BDP-Nitro-CPT in CDCl3 1 H NMR spectrum;

[0039] Fig.12 For the compound BDP-Nitro-CPT in CDCl3 13 C NMR spectrum;

[0040] Fig.13 This is the HRMS spectrum of the compound BDP-Nitro-CPT. DETAILED DESCRIPTION

[0041] In order to make the contents of the present invention easier to understand, the technical solution of the present invention is further described below in conjunction with specific implementation methods, but the present invention is not limited thereto.

[0042] The specific preparation process of the nitroreductase-activated multifunctional molecular prodrug fluoroboron dipyrrole-nitrobenzene-camptothecin conjugate that can be used to overcome the heterogeneity of tumor oxygen distribution includes:

[0043] (1) Add to a 100mL round-bottom flask, dissolve in acetonitrile, weigh 0.5 equivalents of phosphorus tribromide and dissolve in acetonitrile, then use a constant pressure dropping funnel to drop phosphorus tribromide into the reaction flask under ice bath stirring, and react for 2 hours; after the reaction, remove the solvent acetonitrile, extract the residue three times with dichloromethane and water, collect the organic phase, and remove dichloromethane by rotary evaporation. Use dichloromethane as the eluent, separate by silica gel column chromatography, and then rotary evaporation to obtain a yellow solid compound The yield is 35%-40%;

[0044] (2) The product was dissolved in acetone at a molar ratio of 1:2, and then 10 equivalents of potassium carbonate were added. The reaction solution was refluxed in an oil bath at 60°C for 1 hour. After the reaction was completed, the potassium carbonate was filtered and the solvent was removed. The product was then extracted with dichloromethane and water. The organic phase was dried over anhydrous Na2SO4 and the solvent was removed under reduced pressure. The product was then separated by silica gel column chromatography using dichloromethane-methanol (volume ratio of 50:1) as the eluent to obtain a green solid. The yield was 52%-58%.

[0045] (3) Dissolve in dichloromethane at a molar ratio of 1:2.2, then add 2-3 equivalents of 4-dimethylaminopyridine (DMAP), 3 drops of N,N-diisopropylethylamine (DIPEA) and triphosgene, and vigorously stir the reaction solution for 18-36 hours at room temperature; after the reaction, extract with dichloromethane and water, dry the organic phase over anhydrous Na2SO4, and remove the solvent under reduced pressure; finally, use dichloromethane-methanol (volume ratio of 50:1) as the eluent, and separate by silica gel column chromatography to obtain a fluoroboron dipyrrole-nitrobenzene-camptothecin conjugate. (BDP-Nitro-CPT), with a yield of 69%-74%.

[0046] Example 1

[0047] (1) (0.30g, 1.00mmol) was added to a 100mL round-bottom flask and dissolved with 15mL acetonitrile; then phosphorus tribromide (0.14g, 0.50mmol) was weighed and dissolved in 10mL acetonitrile, and then phosphorus tribromide was added dropwise to the reaction flask with constant pressure dropping funnel under ice bath stirring, and the reaction was continued for 2h; after the reaction was completed, the solvent acetonitrile was removed, and the residue was extracted three times with dichloromethane and water, the organic phase was collected, and dichloromethane was removed by rotary evaporation. Using dichloromethane as the eluent, the yellow solid compound was obtained after separation by silica gel column chromatography and rotary evaporation. (0.13g, 37%). 1 H NMR (500MHz, CDCl3): δ (ppm) = 8.28 (d, 2H, J = 9.0Hz, ArH), 7.69 (d, 2H, J = 9.0Hz, ArH), 7.21 (s,2H,ArH),5.20(s,2H,OCH2),4.69(s,2H,OCH2),4.53(s,2H,CH2Br),2.34(s,3H,CH3). 13 C NMR (150 MHz, CDCl3): δ (ppm) = 152.65, 147.68, 144.41, 135.19, 134.08, 131.84, 131.21, 127.84, 123.88, 74.85, 60.79, 27.96, 20.76. HRMS (ESI): calculated value (m / z [M+Na] + ) is: 388.0160; the actual test value is 388.0145.

[0048] (2) (0.10g, 0.10mmol), (0.074 g, 0.20 mmol) was dissolved in acetone, and then potassium carbonate (0.14 g, 1.0 mmol) was added. The reaction solution was refluxed in an oil bath at 60°C for 1 h. After the reaction was completed, the potassium carbonate was filtered and the solvent was removed. Then, the organic phase was extracted with dichloromethane and water. The organic phase was dried over anhydrous Na2SO4 and the solvent was removed under reduced pressure. Then, dichloromethane-methanol (volume ratio of 50:1) was used as the eluent and separated by silica gel column chromatography to obtain a green solid. (0.071g, 53%). 1 H NMR (400MHz, CDCl3): δ (ppm) = 8.23 ​​(d, J = 8.4Hz, 2H, ArH), 8.10 (d, J = 16.4Hz, 2H, CH = CH), 7.59-7.63 (m, 8H, ArH andCH=CH),7.31(s,1H,ArH),7.30(s,1H,ArH),7.18(d,J=8.4Hz,2H,ArH),7.08(d,J=8.8Hz, 2H,ArH),6.97(d,J=8.8Hz,4H,ArH),5.15(s,2H,OCH2),5.13(s,2H,OCH2),4.76(s,2H,OCH2), 4.20(t,J=4.8Hz,4H,OCH2),3.90(t,J=4.8Hz,4H,OCH2),3.78-3.75(m,4H,OCH2),3.72-3.66 (m,8H,OCH2),3.58-3.55(m,4H,OCH2),3.39(s,6H,OCH3),2.39(s,3H,CH3),1.42(s,6H,CH3); 13 C NMR (150MHz, CDCl3): δ (ppm) = 160.01, 159.38, 153.10, 148.41, 147.64, 144.45, 140.78,138.85,134.98,133.97,132.33,131.04,130.94,129.87,129.84,129. 27,127.78,127.46,123.83,116.10,115.43,114.97,110.17,75.79,71.94,70. 89,70.68,70.59,69.69,67.55,65.75,60.85,59.07,20.89,13.82.HRMS(ESI):C 63 H 68 BBr2F2N3O 13 Theoretical calculated values ​​(m / z[M+H] + ) is 1306.3052; the actual test value is 1306.3081.

[0049] (3) (0.03 g, 0.086 mmol) was dissolved in dichloromethane, and then 4-dimethylaminopyridine (DMAP) (0.03 g, 0.246 mmol) and 3 drops of N, N-diisopropylethylamine (DIPEA) were added and stirred at room temperature for 10 minutes. Then, a dichloromethane solution of triphosgene was added dropwise until the reaction solution became clear. 2a (0.05 g, 0.039 mmol), the reaction solution was vigorously stirred at room temperature for 18 h; after the reaction was completed, it was extracted with dichloromethane and water, the organic phase was dried over anhydrous Na2SO4 and the solvent was removed under reduced pressure; finally, dichloromethane-methanol (volume ratio of 50:1) was used as the eluent, and the fluoroboron dipyrrole-nitrobenzene-camptothecin (BDP-Nitro-CPT) conjugate was obtained by silica gel column chromatography (0.022g, 70%). 1 H NMR (500MHz, CDCl3): δ (ppm) = 8.38 (s, 1H, ArH), 8.14 (d, J = 8.5Hz, 1H, ArH), 8.12 (d, J = 16.5Hz, 2H, CH = CH),7.96-7.94(m,3H,ArH),7.83(t,J=7.5Hz,1H,ArH),7.67(t,J=7.5Hz,ArH),7.63-7.60(m,6H,ArH and CH=CH),7.42(d,J=7.5Hz,2H,ArH),7.32(s,1H,ArH),7.31(s,1H,ArH),7.29(s,1H,ArH),7.15(d,J=8.5Hz,2H,ArH),7.04(d,J=8.5Hz,2H,A rH),6.96(d,J=8.5Hz,4H,ArH),5.72(d,J=17.0Hz,1H,OCH2),5.41(d,J=17.0Hz,1H,OCH2),5.30-5.20(m,4H,OCH2),5.07-5.03(m,4H,NCH2 and OCH2),4.20(t,J=4.0Hz,4H,OCH2),3.90(t,J=4.5Hz,4H,OCH2),3.77(t,J=4.0Hz,4H,OCH2),3.72-3.67(m,8H,OCH2),3.5 7(m,4H,OCH2),3.39(s,6H,OCH3),2.33(s,3H,CH3),2.30-2.13(m,2H,CH2),1.39(s,6H,CH3),0.88(t,J=6.5Hz,3H,CH3); 13C NMR (150MHz, CDCl3): δ (ppm) = 160.01, 160.09, 159.33, 157.29, 153.78, 153.67, 152.22, 148.84, 148.47, 147.55, 14 6.51, 145.60, 143.89, 140.79, 138.94, 138.43, 135.18, 131.59, 132.50, 132.36, 131.28, 130.86, 129.93, 129.50, 12 9.34, 128.48, 128.43, 128.29, 128.26, 127.94, 127.56, 123.54, 120.42, 116.14, 115.46, 115.05, 110.23, 95.78, 78 .13, 76.37, 72.01, 70.95, 70.74, 70.66, 69.75, 67.62, 67.22, 65.83, 50.05, 32.09, 20.85, 13.89, 7.69.HRMS(ESI):C 84 H 82 BBr2F2N5O 18 The theoretical calculated value (m / z[M+H]+) is 1680.3954; the actual measured value is 1680.4090.

[0050] Application Example 1

[0051] The in vitro anticancer activity of the molecular prodrug BDP-Nitro-CPT was studied. This experiment can verify the hypoxia response mechanism and synergistic therapeutic mechanism of the drug and provide an experimental basis for in vivo experiments. The cell viability was determined by the MTT method. MTT (3-(4,5-dimethylthiazole-2)-2,5-diphenyltetrazolium bromide) is a yellow solid, and its aqueous solution can effectively identify living cells in the process of cancer cell inhibition. The detection principle is that the succinate dehydrogenase in the mitochondria of living cells reduces the added MTT to water-insoluble purple crystalline formazan and deposits it in the cells, while dead cells cannot reduce the added MTT due to their damaged cell structure. The cells are treated with MTT solution, and after the living cells produce formazan, dimethyl sulfoxide (DMSO) is added to the cells to dissolve the formazan, and the absorbance value (OD value) at 570nm is detected with a microplate reader. The cell survival rate is plotted against the logarithmic concentration of the drug, and the half inhibitory concentration value (IC 50 Cell viability calculation formula: Cell viability% = (A-A0) / (A1-A0) × 100%; where A is the OD value of the experimental group, A0 is the OD value of the blank group, and A1 is the OD value of the cell control group.

[0052] MTT experiment: Normally grown 4T1 cells (mouse breast cancer cells), HepG2 cells (human liver cancer cells), and HeLa cells (human cervical cancer cells) were selected as cell lines for in vitro activity study. Approximately 7×10 3 Cancer cells were incubated in a cell culture incubator at a constant temperature of 37°C for 24 hours. After the incubation, the old culture medium was replaced with fresh DMEM culture medium containing different concentrations of BDP-Nitro-CPT (or 2a), and the cells were incubated for another 8 hours under normoxia (21% oxygen concentration), mild hypoxia (6% oxygen concentration), or hypoxia (0.1% oxygen concentration). After the incubation, the cells were washed three times with PBS and fresh DMEM culture medium was added. The cells were treated with / without light (660nm, 20mW / cm 2 , 5min). After the illumination, the cells were incubated for 24h. Then, 10μL of MTT (5mg / mL) solution was added to the 96-well plate and incubated for 4h. After the incubation, the medium in the 96-well plate was removed with a pipette and 100μL of DMSO was added to fully dissolve the formazan in the cells. The OD value at 490nm was detected with an enzyme-labeled instrument.

[0053] We used the MTT method to determine the cytotoxicity of the molecular prodrug BDP-Nitro-CPT prepared in the example and the control drug 2a to 4T1 cells, HepG2 cells, and HeLa cells under normal oxygen (21% O2), mild hypoxia (6% O2), and hypoxia (0.1% O2). Figure 1 It can be seen that: under normal oxygen conditions ( Figure 1 In the c, f, i), within the drug concentration range of 0.01-10 μM, BDP-Nitro-CPT and 2a had no significant killing effect on the three cancer cells, indicating that the drugs have good biocompatibility. Figure 1 In a, d, and g), BDP-Nitro-CPT has a certain killing effect on 4T1, HepG2, and HeLa cells, while 2a has no obvious cytotoxicity to the three cancer cells treated under hypoxic conditions. This result shows that under hypoxic conditions, the nitrophenyl group in the BDP-Nitro-CPT prodrug can be reduced by the nitroreductase overexpressed in hypoxic cells, and then release the chemotherapeutic drug camptothecin, inducing cancer cell death. Under light conditions (660nm, 20mW / cm 2 , 5min), BDP-Nitro-CPT had high cytotoxicity against the three cancer cells cultured under normoxic and mild hypoxic conditions. Its IC 50The values ​​were 0.66μM, 0.67μM, and 0.73μM, and the IC values ​​for 4T1, HepG2, and HeLa cells cultured under mild hypoxia conditions were 50 The values ​​were 0.73μM, 0.66μM, and 0.77μM, and their cytotoxicity was higher than that of the control group 2a ( Figure 1 , Table 1). This indicates that BDP-Nitro-CPT can consume oxygen and promote the release of camptothecin during photodynamic therapy, achieving a synergistic effect of photodynamic therapy and chemotherapy. In addition, BDP-Nitro-CPT has an inhibitory effect on the IC 50 The IC value of hypoxic cells treated with 2a was 50 The value is high, indicating that the camptothecin released by BDP-Nitro-CPT prodrug under hypoxic conditions can make up for the shortcomings of photodynamic therapy.

[0054] Table 1. IC values ​​of BDP-Nitro-CPT and 2a for 4T1, HepG2, and HeLa cells 50 value

[0055]

[0056] The in vivo anticancer activity of the molecular prodrug BDP-Nitro-CPT and the control photosensitizer 2a was studied. This experiment can further verify the hypoxia response mechanism and synergistic therapeutic mechanism of the BDP-Nitro-CPT prodrug. This experiment used Balb / c mice for a 15-day anti-tumor effect test. The tumor inhibition effect was judged by observing the changes in tumor size during treatment, the tumor mass of each group of mice after treatment, and H&E staining of tumor tissue sections, and the safety of the drug was evaluated.

[0057] Experimental methods and specific steps:

[0058] (1) Establishment of Balb / c mouse model: 30 5-week-old female Balb / c mice weighing about 20 g were selected and 1×10 6 4T1 mouse breast cancer cells.

[0059] (2) Grouping and Dosing: When the average size of mouse tumors grows to 60 mm 3 The mice were randomly divided into six groups (BDP-Nitro-CPT+Light group, 2a+Light group, BDP-Nitro-CPT group, 2a group, Saline+Light group, Saline group), with five mice in each group in parallel. Each group of mice was given the corresponding drug (100 μL, 100 μM) by tail vein injection.

[0060] (3) Light treatment: The first administration was on day 0. The light treatment group was given light treatment 24 h after administration. A 660 nm laser was used to irradiate the tumor site of the mice for 10 min (power density was 300 mW / cm 2 ).

[0061] (4) Data measurement and recording: After light treatment, the mice were weighed and the tumor volume was measured regularly every day, and this was repeated for 15 days.

[0062] (5) H&E staining: After the treatment, one mouse was randomly selected from each group and killed by cervical dislocation. The tumor, heart, liver, spleen, lung, and kidney were removed and fixed in 4% paraformaldehyde solution for 24 h. The sections were wrapped in paraffin and then stained with H&E. The histological morphology of each tissue section was observed and photographed under an optical microscope.

[0063] The anti-tumor results of the experimental and control groups are summarized in Figure 2 .from Figure 2 It can be seen that compared with the Saline control group, the mice in the Saline+Light group and the group injected with 2a without light had no obvious tumor inhibition effect, indicating that the injection of BDP photosensitizer 2a and light alone had no anti-tumor effect. However, the 2a+light and BDP-Nitro-CPT without light groups had obvious tumor inhibition effects, which is due to the photodynamic therapy and tumor hypoxia-activated chemotherapy, respectively. In contrast, the anti-tumor effect of BDP-Nitro-CPT injected into the tail vein of mice and treated with light was the most significant, and the size and mass of the dissected mouse tumors were also relatively small ( Figure 2 c and b), and even four mice had their tumors completely eliminated and did not recur ( Figure 2 In addition, tumor histological H&E staining showed that the BDP-Nitro-CPT+Light group could induce a large number of tumor cell necrosis and apoptosis ( Figure 2 During the entire treatment period, the body weight of the mice showed negligible fluctuation ( Figure 2 In addition, it can be seen from the tissue sections of various organs that 2a and BDP-Nitro-CPT will not cause damage to normal tissues even under light conditions ( Figure 3 ). The experimental results show that BDP-Nitro-CPT enriched in the tumor area under light has a photodynamic-chemotherapy synergistic therapeutic effect. While enhancing tumor inhibition, BDP-Nitro-CPT exhibits good biosafety.

[0064] The above description is only a preferred embodiment of the present invention. All equivalent changes and modifications made according to the scope of the patent application of the present invention should fall within the scope of the present invention.

Claims

1. A multifunctional molecular prodrug activated by nitroreductase for overcoming the heterogeneity of tumor oxygen distribution, characterized in that: The prodrug is a fluoroboron dipyrrole-nitrobenzene-camptothecin conjugate, and its chemical structure is: 。 2. A method for preparing a multifunctional molecular prodrug activated by nitroreductase for overcoming the heterogeneity of tumor oxygen distribution as claimed in claim 1, characterized in that: The preparation method comprises the following steps: , As the starting material, fluoroboranedipyrrole-nitrobenzene-camptothecin conjugate was synthesized.

3. The preparation method according to claim 2, characterized in that: The preparation method specifically comprises the following steps: , Dissolve in dichloromethane at a molar ratio of 1:2.2, then add 2-3 equivalents of DMAP, 3 drops of DIPEA and triphosgene, and vigorously stir the reaction solution for 18-36 hours at room temperature; after the reaction is completed, extract with dichloromethane and water, dry the organic phase over anhydrous Na2SO4, and remove the solvent under reduced pressure; finally, use dichloromethane-methanol with a volume ratio of 50:1 as the eluent, separate by silica gel column chromatography to obtain fluoroboron dipyrrole-nitrobenzene-camptothecin conjugate.

4. The preparation method according to claim 3, characterized in that: The 2-3 equivalents of DMAP, The molar amount of .

5. The preparation method according to claim 2 or 3, characterized in that: The The preparation method comprises the following steps: (1) , phosphorus tribromide as starting materials, synthesized ; (2) The product synthesized in step (1) , As the starting material, the synthesis .

6. The preparation method according to claim 5, characterized in that: Said The preparation method specifically comprises the following steps: (1) , phosphorus tribromide in a molar ratio of 2:1, and dissolved in acetonitrile, and then reacted for 2 h under ice bath conditions; after the reaction, the solvent was removed, and the mixture was separated by silica gel column chromatography using dichloromethane as the eluent to obtain a yellow solid ; (2) , The product was dissolved in acetone at a molar ratio of 1:2, and then 10 equivalents of potassium carbonate were added. The reaction was refluxed in an oil bath at 60°C for 1 h. After the reaction was completed, the potassium carbonate was filtered and the solvent was removed. The product was then extracted with dichloromethane and water. The organic phase was dried over anhydrous Na2SO4 and the solvent was removed under reduced pressure. The product was then separated by silica gel column chromatography using dichloromethane-methanol in a volume ratio of 50:1 as the eluent to obtain a green solid. .

7. The preparation method according to claim 6, characterized in that: The 10 equivalents of potassium carbonate are Calculate the molar amount.

8. Use of the multifunctional molecular prodrug activated by nitroreductase for overcoming the heterogeneous distribution of oxygen in tumors as claimed in claim 1 in the preparation of drugs against breast cancer, liver cancer and cervical cancer.